Onco-NX, a drug discovery firm spun-out of the University of Salford, has been acquired by UK-based oncology firm Incanthera, itself a spin-out of the University of Bradford.
The sale of the Manchester-based life sciences firm marks the first successful sale of a Salford spin-out, also the university’s first drug development firm, which is developing a therapy which targets solid tumours without affecting health.
Both firms share a common investor, Spark Impact, which manages the North West Fund, a biomedical investment…
